Epstein-Barr virus-induced gene 3 (EBI3) encodes a secretory glycoprotein, and has previously been identified as upregulated in a series of cancers. However, the clinical significance of EBI3 in cervical cancer and the potential of EBI3 as a therapeutic target for this disease have not been elucidated. In the present study, EBI3 expression was analyzed by immunohistochemistry in 90 clinicopathologically characterized cervical cancer tissue samples. The association between EBI3 expression and survival of patients with cervical cancer was also analyzed. The expression level of EBI3 in cervical cancer tissues was found to be significantly increased compared with the expression levels in the normal squamous epithelium. In addition, EBI3 expression was significantly correlated with the clinical stage and size of tumors (P<0.05). Furthermore, the presence of EBI3 expression was associated with a poor prognosis compared with patients without EBI3 expression. Multivariate analysis revealed that EBI3 expression was an independent predictor of overall survival (hazard ratio, 4.032; 95% confidence interval, 1.538-7.436; P=0.035). To the best of our knowledge, the present results indicate for the first time that EBI3 expression is significantly associated with the progression and poor prognosis of cervical cancer. EBI3 may be a potential prognostic marker and a therapeutic target in cervical cancer.
Introduction
Cervical cancer is a malignant tumor that damages the health of women. There is a general consensus that persistent infection with high-risk human papillomavirus is the main method of pathogenesis for cervical cancer (1) (2) (3) (4) (5) . Although a breakthrough has previously been achieved with regard to the etiology of this disease, the cause of the disease has not been fully elucidated. Therefore, it is of considerable importance to identify additional prognostic markers, as well as novel therapeutic methods, for cervical cancer.
In previous studies, Epstein-Barr virus (EBV)-induced gene 3 (EBI3), which was originally cloned as a gene induced in EBV-transformed B cells by the oncogene latent membrane protein 1, demonstrated a restricted expression pattern in B-cell lymphoma (6) (7) (8) (9) . Previously, certain studies have demonstrated that EBI3 expression is also present in lung cancer and colorectal cancer tissues and plays important functions in the progression of these tumors (10, 11) . Using tissue microarrays, Nishino et al also revealed that a high level of EBI3 expression is correlated with an unfavorable poor prognosis in lung cancer patients (10) . Additional studies have confirmed that EBI3 expression is an independent prognostic factor for disease outcome in lung and colorectal cancer, as well as Burkitt lymphoma (10) (11) (12) . However, the clinical significance of EBI3 in cervical cancer and the potential of EBI3 as a therapeutic target for this disease have not been clarified.
These observations prompted the current assessment of the role of EBI3 in cervical cancer. In the present study, the expression pattern of EBI3 in cervical cancer was investigated. In addition, the use of EBI3 as a potential biomarker for cervical cancer was also studied. 
Materials and methods

Expression of Epstein-Barr virus-induced gene 3 in cervical cancer: Association with clinicopathological parameters and prognosis
Quantum dot (QD)-based immunohistochemical study. The QDs conjugated with streptavidin (QDs-SA) probes possessed an emission wavelength of 605 nm. QD-immunohistochemistry (IHC) was performed using a similar procedure to conventional IHC, and the major procedures were as follows: Deparaffinization; antigen retrieval; incubation with primary antibody (polyclonal rabbit anti-human EBI3; catalog no., sc-32868; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), or Tris-buffered saline in the control group; washing; incubation with the biotinylated polyclonal goat anti-rabbit IgG secondary antibody (catalog no., KIT-5905; Maxim-Bio, Fuzhou, Fujian, China); washing; administration of QDs-SA; washing; and observation (13) .
IHC and immunohistochemical analysis. For antigen retrieval, 4-µm tissue sections were microwaved in citrate buffer for 5 min. The sections were incubated with the polyclonal rabbit anti-human EBI3 antibody (dilution, 1:150; catalog no., sc-32868; Santa Cruz Biotechnology, Inc.) for 40 min at room temperature. Antibody labeling was detected by incubating the tissue sections with biotinylated polyclonal goat anti-rabbit IgG secondary antibodies (dilution, 1:50; catalog no., KIT-5905; Maxim-Bio), followed by incubation with the avidin-biotin complex (Maxim-Bio) and diaminobenzidine (Maxim-Bio). The sections were then counterstained with hematoxylin. The expression of EBI3 was scored according to the intensity of staining, as follows: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. The percentage of stained cancer cells was then used to determine the extent of staining, as follows: 0, no stained cells; 1, <10% of cells stained; 2, 10-50% of cells stained; 3, >50% of cells stained; and 4, >75% of cells stained. If the product of the intensity and extent of staining scores was ≥2, the tissue was considered to be positive for the expression of EBI3.
Statistical analysis. Statistical analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). The association between EBI3 expression and the clinicopathological parameters of patients with cervical cancer was evaluated using Fisher's exact test. The Cox proportional hazards regression model was performed for multivariate survival analysis. Overall survival curves were generated according to the Kaplan-Meier method. P<0.05 was considered to indicate a statistically significant difference.
Results
Expression pattern of EBI3 in cervical cancer tissue samples. Immunohistochemical staining for the expression of EBI3 was evaluated in 90 cervical cancer tissue samples. As exhibited in Fig. 1 , the expression of EBI3 was observed in 58 out of the 90 tissue samples (64.4%). However, EBI3 expression was not detected in the normal squamous epithelium. Immunoreactivity for EBI3 was predominantly expressed in the cytoplasm of cancer cells, and not in the nuclei of cancer and stromal cells.
QD-based immunohistochemical study. Previously, QD-based immunohistochemical staining has resulted in a considerable progression in molecular imaging, particularly in studies investigating cancer (13, 14) . In the present study, EBI3 expression was indicated by bright red QD fluorescence and was observed in the cytoplasm of cancer cells (Fig. 2) ; this pattern is consistent with the results of traditional immunohistochemical technology. This result confirmed the expression pattern of EBI3 in cervical cancer cells.
Association between EBI3 expression and the clinicopathological factors of patients with cervical cancer. The expression rates of EBI3 in cervical cancer tissue samples were associated with clinicopathological features are presented in Table I . In this assay, EBI3 expression was observed to be significantly associated with the clinical stage (P=0.024) and size (P=0.022) of the cervical cancer tumors. By contrast, there was no significant association between the expression of EBI3 and other clinicopathological parameters, including patient age, pathological tumor grade and presence of lymph node metastasis (P>0.05).
Effect of EBI3 expression on the overall survival in patients
with cervical cancer. The role of EBI3 as a predictor of disease outcome was studied in cervical cancer patients. Univariate Cox regression analysis demonstrated that the clinical stage, presence of lymph node metastasis and expression of EBI3 were significantly associated with the overall survival rate of patients with cervical cancer. As features that are observed to exert a prognostic effect in univariate analysis may covariate, the clinicopathological factors that were significantly associated with outcome in univariate analysis were further examined using multivariate analysis (Table II ). The results indicated that EBI3 expression was an independent prognostic factor for poor survival in patients with cervical cancer (hazard ratio, 4.032; 95% confidence interval, 1.538-7.436; P=0.035) (Table II) . The clinical stage and presence of lymph node metastasis were also confirmed to be independent predictors for patient survival (P<0.05). In all clinicopathological parameters, the presence of lymph node metastasis was the most significant independent parameter for the prediction of prognosis (P=0.013).
To elucidate the prognostic role of EBI3 in cervical cancer, the overall patient survival time was estimated using Kaplan-Meier survival curves. As shown in Fig. 3 , patients that expressed EBI3 demonstrated a shorter overall survival time compared with patients that without EBI3 expression (P<0.05) (Fig. 3 ).
Discussion
Previously, certain studies have revealed the presence of EBI3 overexpression in a series of tumors (8) (9) (10) (11) . EBI3 was also found to be highly expressed in patients with non-small cell lung cancer (10) . Furthermore, strong EBI3 expression in lung cancer tissues has been revealed to be correlated with a poor patient prognosis (10) . The expression of EBI3 has also been identified in Hodgkin's lymphoma and acute myeloid leukemia cells (7, 15) . However, the expression pattern of EBI3 and the clinical significance of EBI3 expression in cervical cancer remains to be elucidated.
Interleukin (IL)-35 is a member of the IL family and exerts an immunosuppressive function on regulatory T cells (16) (17) (18) (19) (20) (21) .
Previously, a series of findings revealed that IL-35 is a vital component in the development and progression of cancers, including colorectal and pancreatic cancer (11, 22) . As a secretory glycoprotein, EBI3 dimerizes with p35-associated subunits to form IL-35 cytokines (23) . With consideration of the notable role of IL-35 in cancer, it was hypothesized that EBI3, a component of IL-35, may also participate in the tumorigenesis of cervical cancer. Long et al reported that upregulated expression of EBI3 promotes the growth of lung cancer cells, while knockdown of EBI3 inhibits the 
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proliferation of lung cancer cells (22) . However, the precise function of EBI3 is not well understood in cervical cancer.
To the best of our knowledge, the present study is the first to report the EBI3 expression pattern in cervical cancer. In the current study, EBI3 staining was observed in 64.4% of the cervical cancer tissue specimens. In addition, EBI3 expression was confirmed to be significantly associated with the tumor size and clinical stage, as well as a poor prognosis in cervical cancer patients. The present results demonstrated that EBI3 is involved in the progression of cervical cancer. Nishino et al previously revealed that the lung cancer COS-7 cell line, which expresses exogenous EBI3, exhibited significant rapid cell growth compared with control mock cells. Furthermore, cells that stably expressed EBI3 formed larger colonies compared with the control cells, indicating the potential oncogenic effect of EBI3 in lung cancer. By contrast, knockdown of EBI3 expression by small interfering RNA significantly inhibited the growth of lung cancer cells (10) . The present results suggested that EBI3 expression was associated with an increased tumor size, and also confirmed that EBI3 may be involved in the growth of cervical cancer cells. In lung cancer patients, serum EBI3 was identified as a single-tumor marker for early stage lung cancer (10) . However, the present data indicated that the positive rate of EBI3 was significantly increased in advanced-stage cervical cancer tissue samples compared with the rate in early-stage cervical cancer tissues. One reason for this discrepancy between studies may be the various types of cancers investigated.
In conclusion, the present study demonstrated that EBI3 is highly expressed in cervical cancer tissues. In addition, EBI3 was identified as a prognostic biomarker for cervical cancer and it may be a possible target for the treatment of cervical cancer. A B
